DTPa-HBV-IPVHib vaccine (Infanrix hexa ™): A guide to its use in infants

Pediatric Drugs

Volumn 14, Issue 5, 2012, Pages 337-343

  Lyseng Williamson, Katherine A ^a   Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Clinical Q and A; Children; Diphtheria; Haemophilus infections; Hepatitis B; Hib DTaP hepatitis B poliovirus vaccine; Infants; Pertussis; Poliomyelitis

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA VACCINE; EXCIPIENT; HAEMOPHILUS INFLUENZAE VACCINE; HEMAGGLUTININ; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; NEOMYCIN; PERTACTIN; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYMYXIN; TETANUS TOXOID; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DTPA HBV IPV COMBINED VACCINE; DTPA-HBV-IPV COMBINED VACCINE; HAEMOPHILUS VACCINE; VACCINE;

ANTIBODY TITER; APPLICATION SITE SWELLING; ARTICLE; BRAIN DISEASE; CLINICAL STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DIPHTHERIA; DRUG CONTRAINDICATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG STORAGE; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; PAIN; PAPILLOMAVIRUS INFECTION; PATHOLOGICAL CRYING; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SIDE EFFECT; SKIN REDNESS; TETANUS; TETANUS PROPHYLAXIS; VACCINATION; VOMITING; WORLD HEALTH ORGANIZATION; HAEMOPHILUS INFECTION; IMMUNIZATION; IMMUNOLOGY;

DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; TETANUS; VACCINES, COMBINED; WHOOPING COUGH;

EID: 84865367550     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11210000-000000000-00000     Document Type: Article

References (47)

1. World Health Organization. Table 2: Summary of WHO position papers. Recommended routine immunizations for children [online]. Available from: http://www.who.int/immunization/policy/Immunization-routine-table2.pdf [Accessed 2012 Jun 14]
2. Global immunization vision and strategy: 2006-2015. Geneva: World Health Organization, 2005 Oct
3. Infanrix hexa: summary of product characteristics. London: European Medicines Agency, 2011 Sep 14
4. Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006 Jun; 256): 507-12
5. Zepp F Knuf M HeiningerU et al. Safety reactogenicity immunogenicity of Combined Hexavalent Tetanus Diphtheria Acellular Pertussis Hepatitis B Inactivated Poliovirus Vaccine Haemophilus Influenzae Type B Conjugate Vaccine For Primary Immunization Of Infants. Vaccine 2004 Jun 2; 22 17-18) 2226-33
6. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000 Sep; 1373): 304-12
7. Ari'stegui J Dal-Ré R Di'ez-Delgado J et al. Comparison of the reactogenicity immunogenicity of a combined diphtheria tetanus acellular pertussis hepatitis B inactivated polio DTPa-HBV-IPV) vaccine mixed with the Haemophilus influenzae type b njugate vaccine administered as Single Injection With The DTPa-IPVHib Hepatitis B Vaccines Administered In Two Simultaneous Injections To Infants At 2 4 6 Months Of Age. Vaccine 2003 Sep 8; 2125-26) 3593-600
8. Avdicová M, Prikazský V, Hudecková H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002 Nov; 161 11): 581-7
9. Gabutti G, Zepp F, Schuerman L, et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 2004; 36 8): 585-92
10. Heininger U, Sä nger R, Jacquet JM, et al. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007 Jan 22; 256): 1055-63
11. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2006 Nov 31; 26): 249-54
12. Van Der Meeren O, Kuriyakose S, Kolhe D, et al. Immunogenicity of Infanrix hexa administered at 3, 5 and 11 months of age.Vaccine 2012 Apr 5; 3017): 2710-4
13. PichicheroME, BlatterMM,ReisingerKS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002 Sep; 219): 854-9
14. Lim FS, Han HH, Jacquet JM, et al. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria- tetanusacellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Ann Acad Med Singapore 2007 Oct; 3610): 801-6
15. Omenaca F, Garcia-Sicilia J, Boceta R, et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007 Sep; 269): 824-9
16. Omenaca F, Garcia-Sicilia J, García-Corbeira P, et al. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics 2007 Jan; 1191): E179-85
17. Omenaca F, Garcia-Sicilia J, García-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: First experiences and solutions to a serious and sensitive issue. Pediatrics 2005 Dec; 1166): 1292-8
18. Vazquez L, Garcia F, Ruttimann R, et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in lowbirth- weight premature infants. Acta Paediatr 2008 Sep; 97 9): 1243-9
19. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006; 81 47): 445-52
20. Zinke M, Disselhoff J, Gartner B, et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBVIPV/ Hib. Hum Vaccin 2010 Feb 18; 6 2): 189-93
21. Gustafsson L, Hessel L, Storsaeter J, et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006 Sep; 1183): 978-84
22. Avdicova M, Crasta P, Hardt K, et al. Lasting immune memory against hepatitis B 10 years after the 2+1 primary vaccination schedule with DTPa-HBVIPV/ Hib or DTPa-IPV/Hib+HBV [abstract no. A-435-0028-00311 plus poster]. 30th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2012 May 8-12; Thessaloniki
23. Steiner M, Ramakrishnan G, Gartner B, et al. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa- HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10: 9
24. Zinke M, Kappes R, Kindler K, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009 Sep; 59): 592-8
25. Zepp F, Schmitt HJ, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexa DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009 Jun; 8 6): 663-78
26. Nolan T, Altmann A, Skeljo M, et al. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004 Nov 15; 23 1): 14-20
27. Pichichero ME. Booster vaccinations: Can immunologic memory outpace disease pathogenesis? Pediatrics 2009; 124 6): 1633-41
28. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2005 Jan; 24 1): 70-7
29. Knuf M, Habermehl P, Cimino C, et al. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006 May 29; 24 22): 4727-36
30. Whelan J, Hahné S, Berbers G, et al. Immunogenicity of a hexavalent vaccine co-administered with 7-valent pneumococcal conjugate vaccine: Findings from the National Immunisation Programme in the Netherlands. Hum Vaccin Immunother 2012 Jun 1; 86)
31. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine PHiDCV). Pediatr Infect Dis J 2009 Apr; 28 Suppl. 4: S97-108
32. van den Bergh MR Spijkerman J Swinnen K et al. Immunogenicity of Booster Dose Of 10-valent Pneumococcal Nontypeable Haemophilus Influenzae Protein D-conjugate Vaccine PHiD-CV) In Dutch Children Abstract No. 317. 8th International Symposium On Pneumococci Pneumococcal Diseases; 2012 Mar 11-15; Iguaçu Falls
33. Gimenez-Sanchez F Kieninger DM Kueper K et al. Immunogenicity of Combination Vaccine Containing Diphtheria Toxoid Tetanus Toxoid Threecomponent Acellular Pertussis Hepatitis B Inactivated Polio Virus Haemophilus Influenzae Type B When Given Concomitantly With 13-valent Pneumococcal Conjugate Vaccine. Vaccine 2011 Aug 11; 29 35) 6042-8
34. Tregnaghi MW, Sáez-Llorens X, Abate H, et al. Immungenicity profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine PHiD-CV) in Latin American children enrolled in COMPAS [abstract]. 7th World Congress of the World Society for Pediatric Infectious Diseases WSPID); 2011 Nov 16-19; Melbourne
35. Tejedor JC,Omenaca F,Garci'a-Sicilia J, et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanusacellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 2004 Dec; 23 12): 1109-15
36. Tejedor JC Omenaca F Garci'a-Sicilia J et al. Antibody persistence after primary vaccinationwith a hexavalentDTPa-HBV-IPVHiB vaccine coadministered with Eningococcal C-CRM197 Vaccine Response To A DTPa-IPVHiB Booster At 18 Months Of Age. Pediatr Infect Dis J 2006 Oct; 25 10) 943-5
37. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria- tetanusacellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006 Aug; 25 8): 713-20
38. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011 Jun 6; 29 25): 4264-73
39. Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007 Aug; 166 8): 857-64
40. Vesikari T, KarvonenA, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010 Jul 19; 28 32) 5272-9
41. Kalies H, Grote V, Siedler A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 2008 May 12; 26 20): 2545-52
42. Schmitt HJ, von Kö nig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996 Jan 3; 275 1): 37-41
43. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis.N Engl J Med 1996 Feb 8; 334 6): 341-8
44. SaengerR,MaechlerG,PotreckM,et al.Booster vaccination with hexavalentDTPa- HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa- IPV/Hib+HBV administered separately. Vaccine 2005 Jan 19; 23 9): 1135-43
45. von Kries R Toschke AM Strassburger K et al. Sudden unexpected deaths after the administration of hexavalent vaccines ria tetanus pertussis poliomyelitis hepatitis B Haemophilus influenzae type b) is there Signal? Eur J Pediatr 2005 Feb; 164 2) 61-9
46. von Kries R. Comment on B. Zinka et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination [letter]. Vaccine 2006 Jul 26; 24 31-32): 5783-4; author reply 5785-6
47. Dhillon S. DTPa-HBV-IPV/Hib Vaccine Infanrix hexa: A review of its use as primary and booster vaccination. Drugs 2010; 70 8): 1021-58